| Serial Number | 98727351 |
| Word Mark | RITE3 |
| Filing Date | Friday, August 30, 2024 |
| Status | 688 - NOTICE OF ALLOWANCE - ISSUED |
| Status Date | Tuesday, October 14, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, August 19, 2025 |
| Goods and Services | drug discovery, pharmaceutical drug development, and drug validation services in the field of targeted disease-causing or disease-associated protein degradation; pharmaceutical research and development services, in particular for identifying ubiquitin ligases; providing medical research and scientific information related to ubiquitin ligase identification and targeted disease-causing or disease-associated protein degradation in the fields of pharmaceuticals, biological life sciences, chemistry, biochemistry, biotechnology, and clinical trials; providing scientific, and medical research information related to targeted disease-causing or disease-associated protein degradation in the field of pharmaceutical and clinical trials via the internet; consulting services in the fields of pharmaceutical research, biological life sciences, pharmaceutical chemistry, biochemistry, biotechnology, clinical trials, all related to targeted disease-causing or disease-associated protein degradation; research and development of new products in the field of targeted disease-causing or disease-associated protein degradation and the identification of ubiquitin ligases; pharmaceutical, scientific, medical, and clinical research and development services in the field of targeted disease-causing or disease-associated protein degradation; providing information about scientific, pharmaceutical, clinical, and medical research, namely, drug discovery, development and validation information related to a method of ligase selection to discover molecules and drugs that cause targeted disease-causing or disease-associated protein degradation; Scientific and technological services, namely, technical biology consulting services, in particular for identifying ubiquitin ligases |
| Pseudo Mark | RITE THREE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, August 30, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | SEED Therapeutics US, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | King of Prussia, PA 19406 |
| Party Name | SEED Therapeutics US, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | King of Prussia, PA 19406 |
| Event Date | Event Description |
| Friday, August 30, 2024 | NEW APPLICATION ENTERED |
| Wednesday, March 12, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, March 13, 2025 | ASSIGNED TO EXAMINER |
| Thursday, March 13, 2025 | NON-FINAL ACTION WRITTEN |
| Thursday, March 13, 2025 | NON-FINAL ACTION E-MAILED |
| Thursday, March 13, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, June 12, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, June 12, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, June 12, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, July 16, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, August 13, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, August 19, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, August 19, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, October 14, 2025 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Wednesday, October 15, 2025 | TEAS STATEMENT OF USE RECEIVED |